Wednesday, April 16, 2014

Cynapsus completes $25-million financing

Cynapsus completes $25-million financing

April 15, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has completed the sale of 38,461,538 units at a price of 65 cents each for gross proceeds of $25-million.  Each unit consists of one common share and one warrant.  Each warrant can be exercised to purchase an additional common share during the next 60 months. The offering was led by M Partners […]

Roth starts AcelRx Pharma at buy

Roth starts AcelRx Pharma at buy

April 14, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and $22 price target. The stock closed at $10.32 on Friday. “We believe Zalviso is a disruptive technology that will transform the way many hospitals treat patients with moderate-to-severe acute pain, primarily in the postoperative setting, by providing a solution demonstrated to […]

Leerink starts Kindred Biosciences at outperform

Leerink starts Kindred Biosciences at outperform

April 14, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Kindred Biosciences (NASDAQ:KIN) with an “outperform” rating and a $32 price target based on a forecast of discounted cash flow. The stock closed at $14.66 on Friday. Kindred is focused on bringing therapies for the treatment of dogs, cats, and horses to market. “With three products in pivotal […]

Roth starts Flamel Technologies at buy

Roth starts Flamel Technologies at buy

April 11, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Flamel Technologies (NASDAQ:FLML) with a “buy’ rating and $20 price target. The stock closed at $13.74 on Thursday. “The impetus for our buy rating is the potential for the company’s Eclat division to drive significant, and near-term, EPS profitability,” writes analyst Scott Henry. “The company’s longer-term pipeline […]

SQI Diagnostics completes equity financing

SQI Diagnostics completes equity financing

April 10, 2014 by · Leave a Comment 

Tweet SQI Diagnostics (TSX-V:SQD) has closed a public offering of 8.4 million units at a price of 50 cents each for gross proceeds of $4.2-million. Each unit consists of one common share and one warrant, which can be exercised to purchase an additional common share at a price of 65 cents until April 10, 2016. […]

M Partners starts Aurinia at buy

M Partners starts Aurinia at buy

April 10, 2014 by · Leave a Comment 

Tweet M Partners has initiated coverage of Aurinia Pharmaceuticals (TSX-V:AUP) with a “buy” rating and target price of $6.15. The stock closed at $3.20 on Wednesday. Analyst Daniel Pearlstein writes that the company’s voclosporin drug candidate, which is scheduled to begin a Phase 2b study for the treatment of lupus nephritis, has a wealth of […]

Leerink starts Ignyta at outperform

Leerink starts Ignyta at outperform

April 9, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Ignyta (NASDAQ:RXDX) with an “outperform” rating and $14 valuation. The stock is changing hands at $6.63 on Wednesday afternoon. Given many historical precedents, Ignyta’s targeted therapy in oncology has a “better than average chance of success despite that the lead compound RXDX-101 is still in early stage development,” […]

Cynapsus files final short-form prospectus for offering

Cynapsus files final short-form prospectus for offering

April 9, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has filed a final short-form prospectus in British Columbia, Alberta and Ontario to sell a minimum of 23,076,923 units and a maximum of 38,461,538 units at a price of 65 cents each for gross proceeds of $15-million to $25-million. Each unit consists of one common share and one warrant. Each […]

CombiMatrix names Sahoo head of cytogenetics

CombiMatrix names Sahoo head of cytogenetics

April 9, 2014 by · Leave a Comment 

Tweet CombiMatrix (NASDAQ:CBMX) has named Dr. Trilochan Sahoo as director of cytogenetics, reporting to CMO Dr. Wes Tyson. Dr. Sahoo was previously senior director, clinical cytogenetics, with Quest Diagnostics Nichols Institute in San Juan Capistrano, California. He has written more than 60 published research papers, most of them in the field of molecular cytogenetics, which […]

Avita Medical releases new version of ReCell

Avita Medical releases new version of ReCell

April 8, 2014 by · Leave a Comment 

Tweet Avita Medical (ASX:AVH; OTCQX:AVMXY) has developed and released a new version of ReCell “Spray-on Skin” that no longer requires refrigeration in order to improve the commercial and practical benefits to clinicians. The new version of ReCell has been cleared for use and is starting to be sold in the U.K. and Europe. Avita is […]

Next Page »

Google+